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Prevalence of  
Human Bocavirus 
in Human Tonsils 
and Adenoids
To the Editor: Recently, Longtin 
et al. (1) reported a high rate (43%) of 
human bocavirus (HBoV) infection in 
a group of children chosen to serve as 
controls in a study of HBoV preva-
lence among hospitalized children and 
adults.  In  contrast,  previous  reports 
had found low HBoV prevalence rates 
of 0%–1% in control groups (2,3). At-
tempting to explain this surprising dif-
ference in rates, Lu et al. (4) suggested 
that selection of control patients may 
be related to the difference in rates. 
The control group used in the Long-
tin study was primarily (71%) made 
up  of  children  undergoing  elective 
surgery; previous studies had selected 
control groups from other sources, in-
cluding well children on routine visits 
and  outpatients  with  nonrespiratory 
symptoms. Because the Longtin study 
surgeries were mainly tonsillectomies, 
adenoidectomies, and myringotomies, 
Lu et al. examined the possibility that 
tonsillar tissues, which include the ad-
enoids, are sites of persistent HBoV 
infection. When these researchers ex-
tracted  DNA  from  tonsillar  lympho-
cytes obtained from pediatric patients 
who had undergone tonsillectomies or 
adenoidectomies, they detected HBoV 
DNA in 32% of the samples (4). These 
findings  strongly  suggest  a  connec-
tion between HBoV and tonsillar tis-
sue. Therefore, we tested a number of 
tonsillar samples for the presence of 
HBoV DNA.
Sample acquisition was approved 
by the Nationwide Children’s Hospi-
tal Institutional Review Board. Tonsils 
and adenoids were obtained from 91 
patients who underwent elective sur-
gery  at  Nationwide  Children’s  Hos-
pital  from  June  through  September 
2004. Patients’ ages ranged from 1 to 
16 years (median 5.9 years; age was 
unknown for 4 patients).
Samples  consisted  of  surgically 
removed  tonsil  or  adenoid  tissues. 
DNA was extracted and its concentra-
tion was determined as previously de-
scribed (5). Two primer sets were used 
for HBoV detection by using real-time 
PCR with SYBR Green detection and 
melting-point  determination.  We  de-
signed primers 3097F (5′-GTC-CAA-
TTA-CAT-GAT-CAC-GCC-TAC-TC) 
and 3420R (5′-TGC-GTC-CAC-AGT-
ATC-AGG-TTG-TTG)  that  targeted 
the viral protein 1/2 (VP1/VP2) region 
of  HBoV.  The  nonstructural  protein 
1  (NP1)  region  was  targeted  by  us-
ing primers 188F and 542R from Al-
lander et al. (6) Each 20-μL reaction 
contained SYBR Green JumpStart Taq 
ReadyMix  (Sigma,  St.  Louis,  MO, 
USA), 4 mmol/L MgCl2, 250 nmol/L 
primers, double-distilled H2O, and 2 μL 
of DNA (50–200 ng) cycled on an ABI 
PRISM 7900HT (Applied Biosystems, 
Foster City, CA, USA) instrument at 
94oC for 2 min, followed by 40 cycles 
of 94°C for 20 s, 60°C (NP1 primers) 
or 68°C (VP1/VP2 primers) for 20 s, 
and 72°C for 14 s. Amplification and 
melting  curves  were  analyzed  with 
7900HT version 2.2.1 software (Ap-
plied  Biosystems);  positive  samples 
were  verified  by  sequence  analysis. 
Sequenced  VP-  and  NP1-generated 
amplicons were 99%–100% identical 
to HBoV strain ST1 (6). The detec-
tion sensitivities of the VP and NP1 
assays, determined by using a plasmid 
construct  containing  the  full  HBoV 
genome, were 1–5 and 5–10 gene cop-
ies/reaction, respectively.
Our  testing  identified  HBoV 
DNA in 5 (5.5%) of the 91 children 
who  underwent  elective  tonsillecto-
my/adenoidectomy. Ages ranged from 
1.9 to 4.6 years (median 3.4 years). 
The reason for the much lower HBoV 
prevalence in this group of children, 
compared with prevalences found in 
studies by Longtin et al. and Lu et al., 
is unclear. Lu et al. (4) reported a much 
higher  HBoV  rate  of  lymphocytes 
from adenoids (56%) than from ton-
sils (16%). Although we did not know 
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the exact tissue type of each sample, 
only  that  tonsils,  adenoids,  or  both 
combined could be present, the 5.5% 
rate we found was about one third the 
rate found in tonsil lymphocytes and 
about one tenth the rate found in ad-
enoid lymphocytes.
A seasonal effect may contribute to 
the large discrepancies found in HBoV 
prevalences.  Apparently,  viruses  can 
persist in tonsillar tissue well after the 
symptomatic phase of illness. In chil-
dren with no signs of acute respiratory 
infection, Drago et al. (7) reported that 
45.5% of samples contained viral nu-
cleic acid. Depending on the duration 
of persistence, asymptomatic children, 
sampled shortly after the season of the 
virus in question, would be more likely 
to have detectable virus in their tonsillar 
tissue. The Longtin et al. study samples 
were collected from December through 
April; our study samples were collected 
from June through September. If HBoV 
is seasonal, as has been suggested (3), it 
may have been circulating in the target 
population before samples were taken 
and persisted only in tonsillar tissues. 
Thus,  if  tonsillar  tissue  from  asymp-
tomatic children was obtained within 
the persistence period after the HBoV 
season, samples would be HBoV posi-
tive;  those  obtained  shortly  after  the 
persistence period would have a much 
lower rate.
Differences in patient age in the 
3 studies may also have contributed 
to  the  different  rates  observed.  The 
Longtin et al. group was substantial-
ly  younger  (median  age  23  months) 
than the Lu et al. group (median age 
5 years) or our group (median age 5.9 
years). Preliminary seroepidemiology 
reports indicate the presence of HBoV 
antibodies  in  >50%  of  children  2–3 
years of age (8,9).
The  detection  of  HBoV  in  the 
tonsillar  tissues  we  tested  showed  a 
higher rate of infection than would be 
expected in an asymptomatic popula-
tion. However, the rate was far lower 
than that previously reported for ton-
sillar tissues (1,4).  
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Bartonella  
rochalimae and 
Other Bartonella 
spp. in Fleas, Chile
To the Editor: Fleas are involved 
in the natural cycle of different Barto-
nella spp. Among the 20 currently rec-
ognized Bartonella spp., 13 species or 
subspecies have been implicated in hu-
man disease. Recently, B. rochalimae 
was identified in a patient who had re-
ceived numerous insect bites and sub-
sequently had bacteremia, fever, and 
splenomegaly after visiting Peru (1). 
A  recent  study  in  Taiwan  suggested 
that rodents could be a reservoir for B. 
rochalimae (2), but the vector or other 
mechanism  of  infection  remains  un-
known. We amplified B. rochalimae, 
B. clarridgeiae, and B. henselae from 
fleas (Pulex irritans and Ctenocepha-
lides felis) collected in Chile and dis-
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